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Experimental section 
General 
All reactions were performed under argon in oven-dried glassware. Anhydrous solvents were obtained by 
filtration through activated aluminum oxide. Unless stated otherwise all chemicals and solvents were 
purchased from Sigma. Solvents for extractions and flash chromatography were distilled before use.  
Flash column chromatography (FCC) was performed using silica gel (230–400 mesh) from Silicycle. Thin 
layer chromatography was carried out on glass-backed plates precoated with silica gel (0.25mm, UV254) 
from Macherey-Nagel.
  1
H NMR was recorded at 300MHz or 400MHz on a Bruker AC-300 or a Bruker 
DRX-400.  
13
C NMR (75 MHz) was recorded on a Bruker AC-300.  
31
P NMR spectra were recorded at 
121.4 MHz using 85% H3PO4 as an external standard. All spectra were referenced to the signals of the 
corresponding solvent. Chemical shifts are given in ppm (δ scale) and coupling constants (J) in Hz. High 
resolution electrospray ionization (ESI) mass spectra were recorded on a Thermo Scientific LTQ Orbitrap 
XL instrument.  HPLC purification was performed using an Äkta™ basic 10/100 system (Amersham 
Pharmacia Biotech) equipped with a Phenomenex Jupiter semi-preparative RP-HPLC column (5μm, C18, 
300Å). 
 
 
 
Figure S1. Chemical structures of phosphoramidites used in this study. 
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Scheme S1.  Synthesis of a phenothiazine C-nucleoside analogue 
Compound (2) 
Compound 1β (2.0 g, 3.5 mmol), was suspended in MeOH/THF (1:1, 40 mL), NaOMe (0.55 g, 10.2 mmol) 
was added and the reaction was stirred for 12 h. The mixture was concentrated under reduced pressure 
to approximately 5 mL, and purified by FCC, eluting with CHCl3/MeOH (98:2 to 95:5) gave compound 2 
(0.83 g, 72%). 
1
H NMR (300MHz , CDCl3): δ = 7.2 – 7.12 (m, 4H), 6.93 (t, J = 7.5, 1H), 6.79 (m, 2H), 5.08 
(dd, J = 5.7, 10.2 Hz, 1H), 4.40 (m, 1H), 3.98 (m, 1H), 3.76 (m, 1H), 3.36 (s, 3H), 2.22 – 2.10 (m, 2H), 
2.04 – 1.94 (m, 1H).  
13
C NMR (75 MHz , CDCl3): δ 145.6, 135.2, 127.5, 127.1, 125.4, 124.8, 123.7, 
123.1, 122.5, 114.0, 113.9, 87.2, 79.4, 73.7, 63.4, 43.7, 35.3. HRMS (ESI) m/z calcd for C18H20O3NS 
[MH
+
] 330.1158, found 330.1165 
Compound (3) 
Compound 2 (645 mg, 2.0 mmol) was suspended in CH2Cl2 (25 mL), and cooled to 0 ˚C.  To this 
suspension was added 2,6-di-tert-butyl-pyridine (0.82 g, 4.0 mmol) and DMT-triflate (1.1 g, 2.4 mmol) in 
portions.  The reaction was stirred at 0 ˚C for 1 h., and stirred at rt until completion (4 h).  The mixture was 
quenched with methanol (2 mL), diluted with CH2Cl2 and the organic phase was washed with saturated 
aqueous sodium bicarbonate, brine and dried over anhydrous MgSO4. Purification by FCC, eluting with 
hexane/ethyl acetate (90:10 to 20:80 + ~1% NEt3) gave 3 (760 mg, 60%). 
1
H NMR (300MHz , CDCl3): δ = 
7.49 – 7.47 (m, 2H), 7.38 – 7.12 (m, 11H), 6.92 (t, J = 7.5, 1H), 6.87 – 6.74 (m, 6H), 5.09 (dd, J = 5.7, 
10.2 Hz, 1H), 4.41 (m, 1H), 4.04 (m, 1H), 3.80 (s, 6H), 3.37 (s, 3H), 3.36 (s, 3H), 2.20 (m, 1H), 2.01 (m, 
1H), 1.78 (br s, 1H).  
13
C NMR (75 MHz , CDCl3): δ 145.6, 135.2, 127.5, 127.1, 125.4, 124.8, 123.7, 
123.1, 122.5, 114.0, 113.9, 87.2, 79.4, 73.7, 63.4, 43.7, 35.3. 
13
C NMR (75 MHz , CDCl3): δ 158.4, 145.6, 
145.0, 144.8, 136.0, 130.0, 128.1, 127.8, 127.3, 127.0, 126.7, 125.2, 124.7, 123.4, 123.2, 122.3, 113.9, 
113.7, 113.1, 86.2, 86.1, 79.2, 77.4, 77.0, 76.6, 74.5, 64.5, 55.1, 43.7, 35.2.  HRMS (ESI) m/z calcd for 
C39H37O5NS [M
+
] 631.2387, found 631.2379 
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Compound (4) 
To a solution of compound 3 (675 mg, 1.1 mmol) in dry CH2Cl2 (15 mL), cooled to 0 ˚C, was added N,N-
diisopropylethylamine (0.63 mL, 3.5 mmol), followed by 2-cyanoethyl diisopropylethylamine (320 μL, 1.4 
mmol).  The reaction was removed from the ice-bath and stirred for 1.0 h at rt, diluted with CH2Cl2 and the 
organic phase was washed with saturated aqueous sodium bicarbonate, brine and dried over anhydrous 
MgSO4, purified by FCC, eluting with hexane/ethyl acetate (80:20 to 60:40 + ~1% NEt3).  The resulting oil 
was dissolved in a minimal amount of CH2Cl2 and precipitated by the addition of hexane (15 mL), the 
hexane was discarded and the residue was again dissolved in a minimal amount of CH2Cl2 and 
precipitated by the addition of hexane, the hexane was again discarded and the precipitated compound 
was dried under reduced pressure to give 4 (745 mg, 81%). 
1
H NMR (300MHz ,CDCl3): δ = 7.52 – 7.50 
(m, 2H), 7.42 – 7.38 (m, 4H), 7.33 – 7.12 (m, 7H), 6.92 (t, J = 7.4, 1H), 6.87 – 6.77 (m, 6H), 5.11 (m, 1H), 
4.52 (m, 1H), 4.23 (m, 1H), 3.80 (m, 6H),  3.78 – 3.55 (m, 3 H), 3.36 (s, 3H), 3.33 – 3.24 (m, 2H), 2.63 (t, 
J = 6.8 Hz, 1 H), 2.47 (t, J = 6.6 Hz, 1 H), 2.41 – 2.25 (m, 1 H), 2.07 – 1.97 (m, 1H), 1.24 – 1.09 (m, 12 H).  
13
C NMR (75 MHz, CDCl3): δ 158.4, 145.7, 145.2, 144.9, 136.0, 136.0, 130.1, 128.3, 128.2, 127.7, 127.3, 
127.1, 126.7, 125.3, 124.8, 123.5, 123.3, 122.3, 113.9, 113.7, 113.1, 86.1, 85.6, 79.6, 79.6, 76.3, 76.1, 
75.9, 75.6, 64.3, 64.2, 58.4, 58.2, 55.2, 43.3, 43.2, 43.1, 43.1, 35.3, 24.6, 24.5, 24.5, 24.37, 20.4, 20.3, 
20.2, 20.1. 
31
P NMR (121.5 MHz ,CDCl3): δ 148.1, 147.9.  HRMS (ESI) m/z calcd for C48H54N3O6PS [M
+
] 
831.3465, found 831.3466.
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DNA synthesis 
DNA synthesis was performed on a 1.3 µmole scale on a Pharmacia Gene Assembler Plus DNA 
synthesizer following standard phosphoramidite protocols with 5-(ethylthio)-1H-tetrazole (0.25 M in 
CH3CN) as the activator and coupling times of 6 min for the modified building blocks. Cleavage from the 
solid support and final deprotection was achieved with 30 % NH4OH solution (55 °C, 12 h). Sequences 
containing 5-bromouracil were deprotected with 30 % NH4OH solution for 24 h at room temperature in 
order to avoid formation of 5-aminouracil.   Purification was performed by RP-HPLC using A = 0.1 M 
triethylammonium acetate in H2O, pH 7.0; B = 0.1 M triethylammonium acetate in CH3CN/H2O 4:1, pH 
7.0, detection wavelength at 260 nm and 494 for fluorescein containing sequences. A flow rate of 3.5 
ml/min was used.  For oligonucleotides containing one Phen base surrogate a gradient from 0 - 35% B 
over 30 min was used, for oligonucleotides containing three Phen base surrogates a gradient from 0 - 
45% B over 30 min was used.   
UV Melting Curves 
UV melting curves were recorded on a Varian Cary 100-Bio UV/VIS spectrophotometer (Varian Inc.), 
equipped with a Peltier element at 260 nm with a heating/cooling rate of 0.5°C/min.  A cooling/heating 
cycle in the temperature range 10–90 °C was applied.  Tm values were obtained from the maxima of the 
ﬁrst derivatives of the melting curves using WinUV software. To avoid evaporation of the solution, the 
sample solutions were covered with a layer of dimethylpolysiloxane. All measurements were carried out in 
a buffer consisting of 10 mM Na2HPO4, 150 mM NaCl, pH 7.0 at 1.2 μM strand concentration. 
CD spectra 
CD spectra were measured on a JASCO J-715 spectropolarimeter at the temperature indicated using 
quartz cuvettes with a path length of 1 cm. All measurements were carried out in a buffer consisting of 10 
mM Na2HPO4, 150 mM NaCl, pH 7.0 at 4.0 μM strand concentration. 
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Figure S2. CD spectra of Duplexes D1-D9. 
 
 
Table S1. MS data of single strands 1-14 and fragments a and b.  b ss denotes the single stranded 
oligonucleotide. 
ss
b 
Sequence m/z calcd m/z found 
1 5’-GCGATΦAAATGCG-3’ 3874.5 3874.2 
2 3'-CGCTAPtzT
Br
UTACGC-Fluo 4590.0 4589.9 
3 5’-GCGATΦPhenAATGCG-3’ 3917.6 3917.3 
4 3'-CGCTAPtzPhen
Br
UTACGC-Fluo 4642.2 4641.7 
5 5ʹ-GCGATΦAAAAATGCG-3ʹ 4500.9 4500.6 
6 3ʹ-CGCTAPtzTTT
Br
UTACGC-Fluo 5198.4 5198.1 
7 5‘-GCGATΦPhenPhenPhenAATGCG-3‘ 4630.2 4630.0 
8 3‘-CGCTAPtzPhenPhenPhen
Br
UTACGC-Fluo 5354.7 5354.1 
9 5’-GCGATAPhenAATGCG-3’ 
 
4050.7 
 
4050.2 
 
10 3'-CGCTATPhen
Br
UTACGC-Fluo 
 
4555.0 
 
4554.5 
 
11 3'-CGCTAPtzPhenTTACGC-Fluo 
 
4577.3 
 
4576.6 
 
12 5‘-GCGATAPhenPhenPhenAATGCG-3‘ 4763.3 4762.7 
13 3‘-CGCTATPhenPhenPhen
Br
UTACGC-Fluo 5267.6 5266.8 
14 3' CGCTAPtzPhenPhenPhenTTACGC-Fluo 5289.93 
 
5289.4 
 
a 3'-
-
O4P-ACGC-Fluo 1775.3 
 
1775.7 
 
b 3'-
-
O4P-TACGC-Fluo 2079.4 
 
2079.8 
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Irradiation 
The irradiation sample was prepared by mixing a duplex (4 M, 10 mM Na-Pi-buffer, 150 mM NaCl, pH 
7.0) in equimolar solutions of the single strands together and heating them to 90 °C for 5 min. in the dark, 
cooling to room temperature over night. Samples were deoxygenated by bubbling N2 for 30 min. through 
the solution and then irradiated in quartz glass cuvettes (1 cm). Cuvettes with fresh prepared duplexes 
were placed 6 cm in front of a Sylvania Blacklight (F8 8W T5 BL350 G5) equipped with a glass cut-off 
filter (wall thickness 3 mm, ≤ 300nm). The cuvettes were ice cooled to maintain the temperature of the 
irradiated sample at 4 °C. Aliquots (60 l) of the sample solution (1000 l) were taken after 0, 5, 10, 15, 
20, 30, 40, 60 min of irradiation, placed into sterile a container and stored protected from light at room 
temperature. After withdrawing the last aliquot, all samples were treated with piperidine (6.6 l) and 
subsequently heated to 90 °C for 30 min., cooled to RT and lyophilized. 
Gels 
Samples were dissolved in loading buffer (60 l; 900 l of formamide, 100 l EDTA solution pH 8.0) and 
treated with ultrasound for 3 min. at RT. After sonication samples were heated to 60 °C for 10 min. and 
loaded (20 l) onto a gel (19:1 acrylamide-bisacrylamide, 20 % w/v, 8 M urea, 100 mM Tris-borate and 20 
mM EDTA buffer, pH 8.3). Gels were run at 250 V for 2 h and analyzed using a FLA-3000 Phosphor 
Imager (Fujifilm). Band intensities were quantified with ImageJ. Yields were determined by dividing the 
specific fragment area by the total area, where the aliquot without piperidine treatment served as a blank. 
All experiments were performed in triplicates. 
Figure S3. Fluorescence images of 20 % denaturing PAGEs of duplexes D1-D9 and single strands 2, 4, 
6 and 8. Lane 1 represents aliquot without irradiation and piperidine treatment. Lane 2-9 are aliquots 
withdrawn after 0, 5, 10, 15, 20, 30, 40, 60 min of irradiation and treated with 10 % piperidine at 90 °C for 
30 min. Lane 10 represents the specific strand scission fragment a as a reference. 
Duplex D1      Duplex D2  
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Duplex D3      Duplex D4  
    
Duplex D5     Duplex D6 
    
Duplex D7      Duplex D8  
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 Duplex D9 
 
 
Single strand 6    Single strand 8 
    
 Single strand 2    Single strand 4  
    
 
Intra-strand photoaddition 
Duplex 2 (1 mL, 4 M, 10 mM Na-Pi-buffer, 150 mM NaCl, pH 7.0) was deoxygenated by bubbling N2 for 
30 min. through the solution and then irradiated in quartz glass cuvettes (1 cm). Cuvettes with fresh 
prepared duplex was placed 6 cm in front of a Sylvania Blacklight (F8 8W T5 BL350 G5) equipped with a 
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glass cut-off filter (wall thickness 3 mm, < 300nm) and irradiated for 1h at 0 °C. The sample was 
transferred into a sterile container, lyophilized, desalted by sep-pak column and separated by RP-HPLC 
using A = 0.1 M triethylammonium acetate in H2O, pH 7.0; B = 0.1 M triethylammonium acetate in 
CH3CN/H2O 4:1, pH 7.0, with a detection wavelength at 260 nm and 494. A flow rate of 1ml/min. and a 
gradient of 0 - 80% B over 50 min was used. The purified fragment was characterized by MALDI and NSI
-
 
mass spectroscopy.  
ss 4 crosslink (m/z M+Na++3H+ found 5297.07; calcd. 5296.98) 
ss 7 (m/z M+4H+ found 4635.38; calcd. 4634.2) 
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Scheme S2. Proposed structure of the Phenanthrene-uridinyl Adduct 
 
Scheme S3. Proposed radical mechanism for the phenanthrene-uridinyl Adduct formation 
occurring by the formation of the uracil-5-yl radical  
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Scheme S4. Alternative cross-linking mechanism, initiated by a photochemical induced 2+2 
cycloaddition reaction of BrU and a phenanthrenyl unit. This mechanism seems less likely as it 
does not occur with duplexes D6 and D9 containing a dT instead of a BrU unit. 
 
